AUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it will hold a conference call on Thursday, November 7th at 8:30 a.m. Eastern Time.   Event details:  Date:Thursday, November 7thTime:8:30 a.m. Eastern TimeAudio Webcast:https://www.CassavaSciences.com/company-presentationsOrAudio Webcast:https://edge.media-server.com/mmc/p/tzb9j3sy   A replay of the audio webcast will also be available on the "Company Presentations" page of the Cassava Sciences website for 90 days following the webcast. About Cassava Sciences, Inc.Cassava Sciences is a clinical-stage biotechnolo

AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it will hold a conference call on Thursday, August 8th at 8:30 a.m. Eastern Time. Event details follow:Date:Thursday, August 8thTime: 8:30 a.m. Eastern TimeAudio Webcast:https://www.CassavaSciences.com/company-presentationsOr Audio Webcast:https://edge.media-server.com/mmc/p/zjvmjjcr   A replay of the audio webcast will also be available on the Company Presentations page of the Cassava Sciences' website for 90 days following the webcast. About Cassava Sciences, Inc.Cassava Sciences is a clinical-stage biotechnolo

$126.3 Million In Total Gross Proceeds from Warrant Distribution.Over 1,900 Patients with Alzheimer's Disease Are Randomized in Phase 3 Trials of Simufilam.Over 735 Patients Have Completed a Phase 3 Trial of Simufilam. AUSTIN, Texas, May 10, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a biotechnology company focused on Alzheimer's disease, today reported financial results for first quarter ended March 31, 2024. Net income was $25.0 million compared to a net loss of $24.3 million for the same period in 2023. Net cash used in operations was $19.1 million during the first quarter of 2024. Cash use for operations for the first half of 2024 is still expected to be $35 to $

Shareholders of Record Received Warrants to Purchase Shares of Common Stock Warrants Trade on Nasdaq Under the Ticker "SAVAW"Warrant Holders Who Choose to Exercise During an Early Period Will Receive an Additional 0.5 of a Common Share Per Warrant AUSTIN, Texas, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) ("Cassava Sciences" or the "Company") today announced the completion of a previously announced distribution of warrants (the "Warrants") to its shareholders. The Warrants now trade on Nasdaq under the ticker SAVAW. Stockholders received four (4) Warrants for each ten (10) shares of the Company's common stock held as of December 22, 2023 (the "Record Da

AUSTIN, Texas, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced financial results for the second quarter ended June 30, 2021. Net loss for the second quarter ended June 30, 2021, was $5.1 million, or $0.13 per share, compared to a net loss of $1.1 million, or $0.05 per share, for the same period in 2020. Net cash used in operations was $7.4 million during the first six months of 2021. Net cash use for operations for full-year 2021 is expected to be approximately $20 to $25 million, consistent with previous financial guidance. Cash and cash equivalents were $278.3 million as of June

AUSTIN, Texas, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a biotechnology company focused on Alzheimer's disease, will release financial results for the period ending June 30, 2021 on Tuesday, August 3, 2021 before the market opens, followed by a conference call. Remi Barbier, President & CEO, and Eric Schoen, Chief Financial Officer, will host a conference call to review financial results and to preview the Company's growth strategy. The conference call is scheduled to begin at 9:00 am ET on Tuesday, August 3, 2021. Please dial in 15 minutes in advance to ensure a timely connection to the call. Conference call detail a

10-Q - CASSAVA SCIENCES INC (0001069530) (Filer)

8-K - CASSAVA SCIENCES INC (0001069530) (Filer)

8-K - CASSAVA SCIENCES INC (0001069530) (Filer)

8-K/A - CASSAVA SCIENCES INC (0001069530) (Filer)

8-K - CASSAVA SCIENCES INC (0001069530) (Filer)

8-K - CASSAVA SCIENCES INC (0001069530) (Filer)

8-K - CASSAVA SCIENCES INC (0001069530) (Filer)

8-K/A - CASSAVA SCIENCES INC (0001069530) (Filer)

10-Q - CASSAVA SCIENCES INC (0001069530) (Filer)

8-K - CASSAVA SCIENCES INC (0001069530) (Filer)

H.C. Wainwright upgraded Cassava Sciences from Neutral to Buy and set a new price target of $116.00

H.C. Wainwright downgraded Cassava Sciences from Buy to Neutral

B. Riley Securities downgraded Cassava Sciences from Buy to Neutral and set a new price target of $44.00

B. Riley Securities reiterated coverage of Cassava Sciences with a rating of Buy and set a new price target of $72.00 from $108.00 previously

HC Wainwright & Co. reiterated coverage of Cassava Sciences with a rating of Buy and set a new price target of $124.00 from $97.00 previously

Cantor Fitzgerald downgraded Cassava Sciences from Overweight to Neutral and set a new price target of $100.00

Maxim Group reiterated coverage of Cassava Sciences with a rating of Buy and set a new price target of $190.00 from $80.00 previously

B. Riley Securities reiterated coverage of Cassava Sciences with a rating of Buy and set a new price target of $111.00 from $78.00 previously

B. Riley FBR initiated coverage of Cassava Sciences with a rating of Buy and set a new price target of $78.00

JonesTrading initiated coverage of Cassava Sciences with a rating of Buy and set a new price target of $110.00

Ms. Nassif brings an extensive track record of successfully developing commercial strategies for multiple FDA-approved drugs Appointment initiates Cassava's commercial readiness strategy as the Company prepares for first Phase 3 topline data readout before year end 2024 AUSTIN, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer's disease, today announced the appointment of Freda Nassif as Chief Commercial Officer, effective today. As a member of the Company's executive leadership team, Ms. Nassif will report to Richard "Rick" Barry, President and Chief Executive of Cas

AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA), a biotechnology company focused on Alzheimer's disease, today announced that it has reached a settlement with the U.S. Securities and Exchange Commission ("SEC") of negligence-based disclosure charges that resolve a previously-disclosed SEC investigation into statements made by the Company pertaining to the results of its 2020 Phase 2b clinical trial of simufilam and related matters. Two former senior employees of the Company also settled negligence-based disclosure charges brought by the SEC. Cassava, without admitting or denying the SEC's allegations, agreed to pay a mone

AUSTIN, Texas, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a biotechnology company focused on Alzheimer's disease, today announced it has concluded its search for a Chief Executive Officer and that its Board of Directors has named Richard (Rick) Barry as CEO. Mr. Barry has served as a director of Cassava since June 2021. On July 17 of this year, the Board appointed him Executive Chairman of the Board and the Company's principal executive officer and while undertaking a now completed search for a permanent CEO. In keeping with the company's pledge to follow good governance principles, the Company is separating the positions of CEO and Chairman by appointing Cla

Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) today announced that the Board of Directors has appointed Richard (Rick) Barry as Executive Chairman of the Board and as the Company's principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO. Mr. Barry succeeds Remi Barbier, the Company's Chairman, President and CEO, who resigned from the Company and the Board. Mr. Barbier will remain employed by the Company until September 13, 2024 in a

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, April 01, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) investors that a lawsuit was filed on behalf of investors that purchased Cassava securities between August 18, 2022 and October 12, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investo

$121.1 Million In Cash and Cash Equivalents at December 31, 2023, With an Additional $21.8 Million Raised In 2024 From Exercise of Warrants.A Total of Over 555 Study Participants Have Completed Our Phase 3 Studies.Topline Data Readout for Our 52-Week Phase 3 Trial Expected Year-End 2024.Internal Investigation by Outside Counsel Has Found No Evidence to Substantiate Allegations of Research Misconduct by the Company. AUSTIN, Texas, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a biotechnology company focused on Alzheimer's disease, today reported financial and operating results for the full year ended December 31, 2023 and presented corporate updates. "I see Alzhe

AUSTIN, Texas, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced the appointment of three new members to its Board of Directors, effective immediately. Claude Nicaise, MD – Dr. Nicaise has held clinical/regulatory leadership roles that have resulted in 14 new drug approvals in various diseases areas, including neuroscience. Dr. Nicaise was a Senior Vice President of Strategic Development and Global Regulatory Affairs at Alexion Pharmaceuticals from 2008 to 2014. From 1983 to 2008, Dr. Nicaise served in various positions of increasing responsibility at Bristol-Myers Squibb, includ

Chris Cook, A Skilled Litigator, To Join Management Team as General CounselNew Position Is Expected to Be Critical to Operations and Strategic Initiatives AUSTIN, Texas, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced the expansion of its leadership team with the appointment of Christopher Cook as Senior Vice President and General Counsel. This is a newly created position, reporting to Remi Barbier, President & CEO.   "Chris is an accomplished legal advisor, a skilled litigator and a proven leader in legal matters," said Remi Barbier. "We're very excited that Chris will shortly join u

- Mr. Barry To Contribute Additional Board-level Perspective Around Growth, Governance, Sustainability and Societal Goals – AUSTIN, Texas, June 14, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced the appointment of Mr. Richard (Rick) Barry to the Company's Board of Directors, effective June 11, 2021. "We're very pleased to add Rick Barry as an independent director," said Remi Barbier, Chairman of the Board, President & CEO. "Rick is a highly respected and astute long-term investor. He offers the Board significant insights around sustainability and governance frameworks. Commitment starts

AUSTIN, Texas, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the appointment of James Kupiec, MD, to the newly created position of Chief Clinical Development Officer. Dr. Kupiec will lead the Phase 3 clinical development strategy for simufilam, Cassava Sciences’ investigational drug for the treatment of dementia in Alzheimer’s disease. Dr. Kupiec will also serve as a member of the executive management team, reporting to the President & CEO. “We are delighted to have Dr. Kupiec join our team,” said Remi Barbier, Chairman, President & CEO of Cassava Sciences. “Jim’s extensive exp

Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 5 years by 43.6% on an annualized basis producing an average annual return of 56.63%. Currently, Cassava Sciences has a market capitalization of $597.06 million. Buying $1000 In SAVA: If an investor had bought $1000 of SAVA stock 5 years ago, it would be worth $9,083.94 today based on a price of $12.45 for SAVA at the time of writing. Cassava Sciences's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automat

On Monday, Rick Barry, the executive chairman of Cassava Sciences Inc (NASDAQ:SAVA), wrote a letter to shareholders and employees. He said the company is in the final stages of testing its Alzheimer’s drug candidate, simufilam, with significant financial and emotional stakes. The company is conducting Phase 3 trials to demonstrate the drug’s efficacy and safety. Related: Alzheimer’s-Focused Cassava Sciences Faces Controversy as Key Collaborator Accused of Scientific Misconduct. These trials, costing hundreds of millions of dollars, are essential for determining if simufilam can significantly impact the lives of Alzheimer’s patients and their families. Cassava Sciences’ executi

Shares of CrowdStrike Holdings, Inc. (NASDAQ:CRWD) fell sharply during Monday’s session. Guggenheim analyst John Difucci downgraded the stock from Buy to Neutral, while BTIG analyst Gray Powell downgraded the stock from Buy to Neutral. CrowdStrike shares dipped over 11% on Friday after the company suffered a major outage impacting businesses around the world. Selective Insurance Group shares dipped 13.2% to $264.65 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) shares climbed 148% to $1.98 after the company announced new preclinical study results for its novel oral ketamine analog, Ketamir-2. CareMa

U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Monday. Shares of IQVIA Holdings Inc. (NYSE:IQV) rose sharply during Monday's session after the company released better-than-expected second-quarter financial results and raised its 2024 guidance. IQVIA reported a second adjusted EPS of $2.64, up from $2.43, beating the consensus of $2.57. Provider of advanced analytics reported sales of $3.81 billion, beating the consensus of $3.79 billion, according to data from Benzinga Pro. IQVIA Holdings shares jumped 7.4% to $241.07 on Monday. Here are some other big stocks recording gains in today’s session. Tellurian Inc. (NASDAQ:TELL) shares surged 64.5% to

https://www.sec.gov/Archives/edgar/data/1069530/000143774924023128/ex_701112.htm 

HC Wainwright & Co. analyst Vernon Bernardino reiterates Cassava Sciences (NASDAQ:SAVA) with a Neutral.

U.S. stocks traded mixed toward the end of trading, with the S&P 500 falling over 1% on Wednesday. The Dow traded up 0.53% to 41,173.41 while the NASDAQ fell 2.51% to 18,044.33. The S&P 500 also fell, dropping, 1.24% to 5,597.06. Check This Out: Amazon To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Wednesday Leading and Lagging SectorsConsumer staples shares jumped by 1.4% on Wednesday. In trading on Wednesday, information technology shares fell by 3.6%. Top Headline Synchrony Financial (NYSE:SYF) reported better-than-expected second-quarter results on Wednesday. The company posted quarterly net interest income of $4.405 billion, beating the consensus of $4.28

Cassava Sciences Inc (NASDAQ:SAVA) stock is trading lower on Wednesday on a heavy session volume of 14.35 million, as per data from Benzinga Pro. The Board of Directors appointed Richard (Rick) Barry as Executive Chairman and the company’s principal executive officer, effective immediately. The company is searching for a new permanent CEO. Mr. Barry succeeds Remi Barbier, the Company’s Chairman, President, and CEO, who resigned and will remain employed by the Company until September 13, 2024, in a non-executive capacity, without duties or responsibilities. Lindsay Burns, SVP of Neuroscience at Cassava, is also leaving the company. Cassava and Dr. Burns have agreed that she step down